OncoMatch/Clinical Trials/NCT05265273
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Is NCT05265273 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Nipocalimab for myasthenia gravis.
Treatment: Nipocalimab — The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (\<) 18 years of age (globally) and 8 to \<18 years of age (for Unites Stated (US) sites only), the safety and tolerability of treatment with nipocalimab in children and adolescents and to evaluate the pharmacokinetics (PK) of nipocalimab in children and adolescents with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing, stable standard-of-care therapy.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: thymectomy
Exception: thymectomy >12 months prior to screening is allowed
Has had a thymectomy within 12 months prior to screening, or thymectomy is planned during the Active treatment Phase of the study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Phoenix Children's Hospital · Phoenix, Arizona
- Childrens Hospital Los Angeles · Los Angeles, California
- Lucile Packard Children's Hospital Stanford · Palo Alto, California
- UCSF Benioff Children's Hospital · San Francisco, California
- Children's Hospital Colorado · Aurora, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify